Learn

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

  • September 4, 2024
Read More

Article in Fierce Biotech: The Evolving Alzheimer’s Disease Landscape

  • August 26, 2024
Read More

What is Neuritogenesis? How does Neuritogenesis Affect Alzheimer’s Disease?

  • August 16, 2024
Read More

Article: InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

  • July 25, 2024
Read More

InMed’s INM-901 for Alzheimer’s Disease – Preclinical Data Summary

  • July 25, 2024
Read More

Article: InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease

  • July 22, 2024
Read More

InMed Presents at Benzinga’s Healthcare and Biotech Breakthroughs

  • July 2, 2024
Read More

Replay: InMed Presents at Emerging Growth Conference

  • June 14, 2024
Read More

Article: InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Degenerative Diseases

  • June 14, 2024
Read More

Video Presentation: InMed’s INM-901 is a Potential Multi-factorial Approach to Treating Alzheimer’s Disease

  • June 12, 2024
Read More

The Dales Report: InMed Pharmaceuticals and Alzheimer’s Research

  • May 28, 2024
Read More

Drug Discovery Online Article: Cannabinoids Show Promise As New Treatment For Alzheimer’s Disease

  • May 21, 2024
Read More

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

MANUFACTURING

Investor

CORPORATE

Learn

© Copyright 2024 InMed Pharmaceuticals Inc.

Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*